Clinical Trial Update: Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) [Phase 2]

View source ↗

Summary

An extension study of Neurotech's NT-501 CNTF implant for Macular Telangiectasia Type 2 has completed the Phase 2 trial, with results posted in May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia Type

Drugs mentioned

• NT-501 CNTF implant (CNTF implant)

Snippet

Sponsor: Neurotech Pharmaceuticals | Conditions: MacTel (Macular Telangiectasia) Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2025-05-09